Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HOOK
- Price
- 0.76
- Stock movement up
- +0.02 (2.70%)
- Company name
- Hookipa Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.34M
- Ent value
- -14.48M
- Price/Sales
- 0.15
- Price/Book
- 0.10
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -2.80%
- 1 year return
- -90.84%
- 3 year return
- -66.10%
- 5 year return
- -60.55%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
HOOK does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.15 |
| Price to Book | 0.10 |
| EV to Sales | -0.29 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 9.66M |
| EPS (TTM) | -3.46 |
| FCF per share (TTM) | -5.41 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 50.00M |
| Gross profit (TTM) | 47.92M |
| Operating income (TTM) | -46.86M |
| Net income (TTM) | -43.37M |
| EPS (TTM) | -3.46 |
| EPS (1y forward) | -4.80 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.85% |
| Operating margin (TTM) | -93.71% |
| Profit margin (TTM) | -86.74% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 59.75M |
| Net receivables | 24.99M |
| Total current assets | 93.16M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 20.18M |
| Total assets | 109.73M |
| Accounts payable | 8.96M |
| Short/Current long term debt | 2.83M |
| Total current liabilities | 28.57M |
| Total liabilities | 37.93M |
| Shareholder's equity | 71.80M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -67.26M |
| Capital expenditures (TTM) | 614.00K |
| Free cash flow (TTM) | -67.88M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -60.40% |
| Return on Assets | -39.53% |
| Return on Invested Capital | -59.41% |
| Cash Return on Invested Capital | -92.97% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.75 |
| Daily high | 0.81 |
| Daily low | 0.73 |
| Daily Volume | 18K |
| All-time high | 195.10 |
| 1y analyst estimate | 38.75 |
| Beta | 0.83 |
| EPS (TTM) | -3.46 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| HOOK | S&P500 | |
| Current price drop from All-time high | -99.61% | -12.89% |
| Highest price drop | -99.62% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -68.68% | -11.07% |
| Avg time to new high | 125 days | 12 days |
| Max time to new high | 981 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
7.34M
Marketcap category
Small-cap
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Employees
151
Investor relations
-
SEC filings
CEO
Jörn Aldag
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page